or Try an Advanced Search...

    Technical Analysis for TSHA - Taysha Gene Therapies, Inc.

    Grade Last Price % Change Price Change
    D 2.30 -2.13% -0.05
    TSHA closed down 2.13 percent on Thursday, April 25, 2024, on 48 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 9
    *** please verify all earnings dates ***
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical TSHA trend table...
    Date Alert Name Type % Chg
    Stochastic Reached Oversold Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Evening Star Bearish -2.13%
    Wide Bands Range Expansion -2.13%
    50 DMA Resistance Bearish -9.09%
    Spinning Top Other -9.09%
    NR7 Range Contraction -9.09%
    Narrow Range Bar Range Contraction -9.09%
    Lower Bollinger Band Walk Weakness -9.09%
    Older End-of-Day Signals for TSHA ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 16 hours ago
    Lower Bollinger Band Support about 17 hours ago
    Down 5% about 17 hours ago
    Down 3% about 18 hours ago
    Fell Below Previous Day's Low about 18 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    TSHA Chart by TradingView
    Basic chart:

    Profile

    Taysha Gene Therapies, Inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. Taysha Gene Therapies, Inc. was founded in 2019 and is based in Dallas, Texas.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Rare Diseases Gene Therapy Lipid Storage Disorders Monogenic Deficiency Monogenic Diseases Gangliosidosis Gm2 Gangliosidoses Gm2 Gangliosidosis

    Is TSHA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 20 Analysts' Revenue Estimates For Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Are Surging Higher
    Apr 15 Certain Biotech Investors Get an Early Look at Results. Is That Fair?
    Apr 10 Roblox, TAL Education And Other Big Stocks Moving Higher On Wednesday
    Apr 9 Taysha draws bullish view at Piper Sandler on lead asset
    Apr 9 Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Mar 24 News Flash: Analysts Just Made A Notable Upgrade To Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Forecasts
    Mar 21 Taysha Gene Therapies Full Year 2023 Earnings: Beats Expectations
    Mar 20 Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts
    Mar 20 Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2023 Earnings Call Transcript
    Mar 20 Taysha Gene Therapies Shares Jump On Initial Data From First Pediatric Patient With Rare Neurodevelopmental Disorder
    See more TSHA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.89
    52 Week Low 0.5
    Average Volume 3,233,897
    200-Day Moving Average 2.09
    50-Day Moving Average 2.59
    20-Day Moving Average 2.67
    10-Day Moving Average 2.49
    Average True Range 0.27
    RSI (14) 41.52
    ADX 19.37
    +DI 21.53
    -DI 29.82
    Chandelier Exit (Long, 3 ATRs) 2.60
    Chandelier Exit (Short, 3 ATRs) 2.94
    Upper Bollinger Bands 3.19
    Lower Bollinger Band 2.15
    Percent B (%b) 0.14
    BandWidth 38.77
    MACD Line -0.07
    MACD Signal Line 0.00
    MACD Histogram -0.0697
    Fundamentals Value
    Market Cap 430.01 Million
    Num Shares 187 Million
    EPS -2.87
    Price-to-Earnings (P/E) Ratio -0.80
    Price-to-Sales 23.26
    Price-to-Book 5.89
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.62
    Resistance 3 (R3) 2.61 2.49 2.56
    Resistance 2 (R2) 2.49 2.41 2.50 2.54
    Resistance 1 (R1) 2.40 2.36 2.34 2.41 2.53
    Pivot Point 2.28 2.28 2.25 2.29 2.28
    Support 1 (S1) 2.19 2.20 2.13 2.20 2.07
    Support 2 (S2) 2.07 2.15 2.08 2.06
    Support 3 (S3) 1.98 2.07 2.04
    Support 4 (S4) 1.99